Azzad Asset Management Inc. ADV Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Azzad Asset Management Inc. ADV bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,294 shares of the medical device company's stock, valued at approximately $293,000.

Other large investors have also made changes to their positions in the company. Marshall Financial Group LLC grew its stake in shares of DexCom by 6.9% during the first quarter. Marshall Financial Group LLC now owns 14,142 shares of the medical device company's stock valued at $966,000 after acquiring an additional 907 shares in the last quarter. Union Bancaire Privee UBP SA grew its stake in shares of DexCom by 100.2% during the first quarter. Union Bancaire Privee UBP SA now owns 6,005 shares of the medical device company's stock valued at $410,000 after acquiring an additional 3,005 shares in the last quarter. GPS Wealth Strategies Group LLC grew its stake in shares of DexCom by 103.0% during the first quarter. GPS Wealth Strategies Group LLC now owns 3,222 shares of the medical device company's stock valued at $220,000 after acquiring an additional 1,635 shares in the last quarter. Fifth Third Bancorp grew its stake in shares of DexCom by 1.0% during the first quarter. Fifth Third Bancorp now owns 31,656 shares of the medical device company's stock valued at $2,162,000 after acquiring an additional 309 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in shares of DexCom by 0.6% during the first quarter. Assenagon Asset Management S.A. now owns 650,679 shares of the medical device company's stock valued at $44,435,000 after acquiring an additional 3,833 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the sale, the executive vice president now owns 95,602 shares in the company, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the sale, the director now owns 33,411 shares of the company's stock, valued at $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,474 shares of company stock worth $1,887,026 over the last ninety days. Company insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on DXCM. The Goldman Sachs Group began coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Citigroup restated a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Wall Street Zen upgraded DexCom from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Canaccord Genuity Group lifted their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Stock Performance

DXCM stock traded down $0.50 on Wednesday, reaching $81.33. The company's stock had a trading volume of 1,901,443 shares, compared to its average volume of 4,335,182. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $117.49. The company has a market capitalization of $31.89 billion, a P/E ratio of 60.55, a price-to-earnings-growth ratio of 1.77 and a beta of 1.46. The firm has a fifty day moving average of $79.25 and a two-hundred day moving average of $79.38. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period last year, the company earned $0.32 earnings per share. As a group, analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.